Skip to main content

Table 1 Clinical characteristics of asthmatic patients

From: Phosphodiesterase 3 inhibition and cough in elderly asthmatics

            Treatment
Patient number Age (yr) Sex Height (cm) Type Severity Total IgE in serum (IU/ml) Specific IgE in serum Complication of allergic disease RT20-FEV1 (mg/ml)* Bronchodilator response (%)** BDP (μg/day) Theophylline (mg/day) Clenbuterol (μg/day) Carbocysteine (mg/day)
1 81 M 154 Int Moderate 75 - - 2.50 34.0 800 0 40 1500
2 72 F 151 Ext Moderate 464 HD AR 2.50 25.4 800 0 0 0
3 80 F 143 Ext Moderate 3 Mite, HD - 1.25 27.0 800 0 40 0
4 72 F 148 Int Mild 28 - - 0.08 19.4 0 0 0 1000
5 79 F 142 Int Moderate 37 - - 5.00 27.6 800 0 20 1500
6 72 F 150 Int Moderate 57 - - 0.31 22.3 400 0 40 0
7 72 F 147 Ext Moderate 647 HD, Ceder - 0.31 31.8 800 0 20 1500
8 70 F 140 Int Moderate 17 - - 1.25 17.6 800 0 40 1500
9 75 M 162 Ext Moderate 148 HD, Ceder AR 2.50 14.1 800 0 40 1500
10 71 M 165 Ext Moderate 133 Mite, Ceder AR 1.25 14.6 0 0 40 1500
11 80 M 165 Int Moderate 2 - - 2.50 12.6 400 0 0 0
  1. Ext, extrinsic; Int, intrinsic; HD, house dust; AR, allergic rhinitis; BDP, beclomethasone diproprionate inhalation.
  2. *PC20-FEV1 shows concentration of inhaled methacholine causing a 20% fall in FEV1.
  3. **Bronchodilator response means percent increase in forced expiratory volume in 1s (FEV1) from the baseline value after inhalation of 300 μg of salbutamol sulfate.
  4. All patients used inhaled β2-agonists (salbutamol or procaterol) on demand.